<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">
  • Menu
  • crown-logo-symbol-1-400x551

Find it Quickly

Get Started

Select the option that best describes what you are looking for

  • Services
  • Models
  • Scientific Information

Search Here For Services

Click Here to Start Over

Search Here For Models

Click Here to Start Over

Search Here For Scientific Information

Click Here to Start Over

In Vitro

Boost oncology drug discovery with XenoBase®, featuring the largest cell line selection and exclusive 3D organoid models. Benefit from OrganoidXplore™ and OmniScreen™ for rapid, in-depth analysis.

Learn More

In Vivo

Enhance drug development with our validated in vivo models, in vitro/ex vivo assays, and in silico modeling. Tailored solutions to optimize your candidates.

Learn More

Tissue

Experience ISO-certified biobanking quality. Access top biospecimens from a global clinical network, annotated by experts for precise research.

Learn More

Biomarkers and Bioanalysis

Leverage our global labs and 150+ scientists for fast, tailored project execution. Benefit from our expertise, cutting-edge tech, and validated workflows for reliable data outcomes.

Learn More

Data Science and Bioinformatics

Harness your data and discover biomarkers with our top bioinformatics expertise. Maximize data value and gain critical insights to accelerate drug discovery and elevate projects.

Learn More

KRAS

Accelerate innovative cancer treatments with our advanced models and precise drug screening for KRAS mutations, efficiently turning insights into clinical breakthroughs.

Learn More

EGFR

Advance translational pharmacology with our diverse pre-clinical models, robust assays, and data science-driven biomarker analysis, multi-omics, and spatial biology.

Learn More

Drug Resistance

Our suite integrates preclinical solutions, bioanalytical read-outs, and multi-omics to uncover drug resistance markers and expedite discovery with our unique four-step strategy.

Learn More

Patient Tissue

Enhance treatments with our human tumor and mouse models, including xenografts and organoids, for accurate cancer biology representation.

Learn More

Bioinformatics

Apply the most appropriate in silico framework to your pharmacology data or historical datasets to elevate your study design and analysis, and to improve your chances of clinical success.

Learn More

Biomarker Analysis

Integrate advanced statistics into your drug development projects to gain significant biological insight into your therapeutic candidate, with our expert team of bioinformaticians.

Learn More

CRISPR/Cas9

Accelerate your discoveries with our reliable CRISPR solutions. Our global CRISPR licenses cover an integrated drug discovery platform for in vitro and in vivo efficacy studies.

Learn More

Genomics

Rely on our experienced genomics services to deliver high quality, interpretable results using highly sensitive PCR-based, real-time PCR, and NGS technologies and advanced data analytics.

Learn More

In Vitro High Content Imaging

Gain more insights into tumor growth and disease progression by leveraging our 2D and 3D fluorescence optical imaging.

Learn More

Mass Spectrometry-based Proteomics

Next-generation ion mobility mass spectrometry (MS)-based proteomics services available globally to help meet your study needs.

Learn More

Ex Vivo Patient Tissue

Gain better insight into the phenotypic response of your therapeutic candidate in organoids and ex vivo patient tissue.

Learn More

Spatial Multi-Omics Analysis

Certified CRO services with NanoString GeoMx Digital Spatial Profiling.

Learn More

Biomarker Discovery

De-risk your drug development with early identification of candidate biomarkers and utilize our biomarker discovery services to optimize clinical trial design.

Learn More

DMPK Services

Rapidly evaluate your molecule’s pharmaceutical and safety properties with our in vivo drug metabolism and pharmacokinetic (DMPK) services to select the most robust drug formulations.

Learn More

Efficacy Testing

Explore how the novel HuGEMM™ and HuCELL™ platforms can assess the efficacy of your molecule and accelerate your immuno-oncology drug discovery programs.

Learn More

Laboratory Services

Employ cutting-edge multi-omics methods to obtain accurate and comprehensive data for optimal data-based decisions.

Learn More

Pharmacology & Bioanalytical Services

Leverage our suite of structural biology services including, recombinant protein expression and protein crystallography, and target validation services including RNAi.

Learn More

Screens

Find the most appropriate screen to accelerate your drug development: discover in vivo screens with MuScreen™ and in vitro cell line screening with OmniScreen™.

Learn More

Toxicology

Carry out safety pharmacology studies as standalone assessments or embedded within our overall toxicological profiling to assess cardiovascular, metabolic and renal/urinary systems.

Learn More

Our Company

Global CRO in California, USA offering preclinical and translational oncology platforms with high-quality in vivo, in vitro, and ex vivo models.

Learn More

Our Purpose

Learn more about the impact we make through our scientific talent, high-quality standards, and innovation.

Learn More

Our Responsibility

We build a sustainable future by supporting employee growth, fostering leadership, and exceeding customer needs. Our values focus on innovation, social responsibility, and community well-being.

Learn More

Meet Our Leadership Team

We build a sustainable future by fostering leadership, employee growth, and exceeding customer needs with innovation and social responsibility.

Learn More

Scientific Advisory Board

Our Scientific Advisory Board of experts shapes our strategy and ensures top scientific standards in research and development.

Learn More

News & Events

Stay updated with Crown Bioscience's latest news, achievements, and announcements. Check our schedule for upcoming events and plan your visit.

Learn More

Career Opportunities

Join us for a fast-paced career addressing life science needs with innovative technologies. Thrive in a respectful, growth-focused environment.

Learn More

Scientific Publications

Access our latest scientific research and peer-reviewed articles. Discover cutting-edge findings and insights driving innovation and excellence in bioscience.

Learn More

Resources

Discover valuable insights and curated materials to support your R&D efforts. Explore the latest trends, innovations, and expertly curated content in bioscience.

Learn More

Blogs

Explore our blogs for the latest insights, research breakthroughs, and industry trends. Stay educated with expert perspectives and in-depth articles driving innovation in bioscience.

Learn More

  • Platforms
  • Target Solutions
  • Technologies
  • Service Types

Circulating Tumor Cells in Preclinical Mouse Models of Metastasis

metastasis via CTCs, by cells escaping the primary tumor and traveling via blood vessels

metastasis via CTCs, by cells escaping the primary tumor and traveling via blood vesselsExplore the utility of preclinical mouse models of metastasis to study circulating tumor cells (CTCs) and the techniques used to isolate and characterize them.

Preclinical Mouse Models of Metastasis

We’ve previously posted on which preclinical mouse models best recapitulate human metastatic disease progression. In this post, we’re focusing on the use of these models to study circulating tumor cells, including the latest techniques to isolate and characterize CTCs. Isolation and characterization of CTCs at the molecular and functional level shows great promise for therapeutic development in oncology.

Modelling Circulating Tumor Cells In Vivo

At a very basic level, CTCs are cancer cells that have been shed from a primary tumor or metastatic site, which circulate through blood and/or lymphatic vessels as single cells or aggregates. A subset of CTCs survives, extravasates into the interstitial space, and finally forms a tumor in a new and distant microenvironment.

The term “liquid biopsy” was coined to describe the process of detecting, characterizing, and monitoring non-hematological cancers based on CTCs isolated from peripheral blood. Liquid biopsy has attracted a lot of attention from a variety of stakeholders, including drug developers and clinicians. This is because CTCs can serve as drug targets, guide therapeutic cancer care (e.g. evaluate treatment efficacy, adjust treatment based on molecular profile, monitor for residual disease), and reduce the burden associated with traditional tissue biopsies.

Preclinical Models of CTCs

To study CTCs in preclinical mouse models, metastatic disease must be generated in vivo. There are a variety of metastatic models available, each with advantages and disadvantages when it comes to best recapitulating the progression of the human metastatic process.

Once the ideal metastasis model is selected, CTC analysis provides a unique opportunity for developing new biomarkers and characterizing and tracking metastatic disease progression, which can provide key insights for novel clinical treatments. For these reasons, preclinical metastasis models are increasingly being used to study CTCs and are also being directly established using CTCs isolated from patient blood samples or after ex vivo expansion.

Breast Cancer

CTCs were identified in mice using patient-derived xenograft (PDX) models of breast cancer. This type of model provides a constant and renewable source of CTCs, allowing for the study of CTCs and underlying metastatic processes.

CTC cell lines have also been established from breast cancer CTCs and used to identify a potential signature of brain metastasis. CTCs with this signature were found to be highly invasive and generated brain and lung metastases when xenografted into immunocompromised mice. Similarly, breast cancer CTCs were isolated from patients with estrogen receptor–positive breast cancer and used to establish cell lines, 60% of which were tumorigenic in mice.

Lung Cancer

Patient-derived CTCs are being used to generate preclinical mouse models with CTC-derived explants, including for small-cell lung cancer (SCLC), which is known to harbor high levels of CTCs. For instance, patient-derived SCLC CTCs were tumorigenic in immunocompromised animals, and the CTC-derived model mirrored donor patient response to chemotherapy.

Colon Cancer

A permanent cell line from CTCs derived from a colon cancer patient was established sharing the characteristics of the original tumor, and which induced tumors in immunocompromised animals allowing functional studies and drug evaluation.

Enrichment and Characterization of CTCs

Before a CTC study, researchers should familiarize themselves with the techniques commonly used to enrich and characterize CTCs. In particular, enrichment remains a major technical challenge because CTCs are:

  • Rare in the peripheral blood (estimated to occur at ~1 CTC per 105–108 white blood cells).
  • Suspected to have a short half-life.
  • Accompanied by a paucity of reliable surface biomarkers.

However, recent technological advances have helped circumvent some of the challenges and there are commercially available platforms that collect and identify CTCs.

CTCs are usually identified as nucleated cells that express epithelial markers cytokeratin (CK)/EpCAM but not CD45. However, the current drawback of capturing CTCs by the recognition of epithelial-specific markers is the lack of ability to detect CTCs that undergo epithelial-mesenchymal transition (EMT) and no longer overexpress EpCAM. CTCs undergoing EMT acquire mesenchymal morphology which is associated with the apparition of the expression of mesenchymal markers such as vimentin (CSV), Slug, or Twist, that can be use as alternative or complementary methods able to recognize a broader spectrum of phenotypes.

CTC Capture

Immunomagnetic-based enrichment is the most commonly used technique to capture CTCs. It relies on magnetic, bead-based separation technology, where CTCs are enriched from blood samples using antibodies conjugated to magnetic beads. The antibodies select for CTCs either positively, by targeting epithelial or tumor-specific antigens, or negatively by targeting blood cell antigens (e.g. CD45).

Multiple commercial vendors market different products. Notably, some of the positive selection products, such as the EpCAM based systems, target only epithelial cells. Today the CellSearch® CTC Kit is the only FDA-approved strategy to detect CTC of epithelial origin (CD45-, EpCAM+, and cytokeratins 8, 18+, and/or 19+) in whole blood.

Density-based enrichment relies on the CTCs being generally less dense than blood cells. There are several commercial vendors of density gradient media that separate CTCs from blood cells. This technique captures both epithelial and mesenchymal CTCs and is generally simple to use and inexpensive, however the method shows low specificity.

Size-based enrichment relies on the difference in size between CTCs and white blood cells. CTCs are larger than leukocytes and filtration devices have pore sizes that separate the two. This technique captures both epithelial and mesenchymal CTCs and is also generally simple to use and inexpensive. Nevertheless, CTCs of smaller sizes may be lost.

Microfluidic-based enrichment involves passing whole blood through microchannels on chip-based devices. As CTCs travel through the channels, they are captured by antibodies attached to “microposts” or filtered by size. Multiple microfluidic options are commercially available. These devices can handle fluid volume in the µL to nanoliter range, and they generally allow for high enrichment and isolation of intact CTCs.

CTC Characterization

Regardless of the enrichment technique, subsequent downstream characterization (i.e. detection, enumeration, and/or molecular characterization) is required, which is possible using a variety of protein- and/or nucleic-acid-based approaches.

Protein-based detection and molecular characterization is performed via one or more of several techniques. Common options include flow cytometry and slide-based immunofluorescence, which rely on fluorescent-conjugated antibodies that target antigens on CTCs. These are then identified with standard laser- or image-based detection systems.

Nucleic acid-based detection and molecular characterization is typically performed with real-time and quantitative real-time PCR, which identify CTCs based on expression of specific genes. Other techniques, such as next-generation sequencing and other genomic analyses, are increasingly being used. Notably, these assays don’t allow for accurate quantification of CTCs or recovery of CTCs for additional analysis.

In addition to CTCs, liquid biopsies also offer the opportunity to evaluate ctDNA. That is another circulating biomarker that has high sensitivity and may be useful in treatment selection, response monitoring, and monitoring tumor burden and molecular features of disease. Isolation and analysis of ctDNA can be technically less demanding, and each biomarker offers distinct advantages and disadvantages. Therefore, researchers should give careful consideration to selecting the biomarker that will offer the best opportunity to achieve their specific study objectives.

Summary

Preclinical mouse models of metastasis are invaluable for the study of CTCs and they are increasingly being used to study them. Once a suitable metastasis model is selected, CTC analysis can be leveraged to develop novel biomarkers and characterize and track metastatic disease progression.

Furthermore, there are several options for researchers to consider when it comes to the isolation and characterization of CTCs. Researchers should familiarize themselves with the advantages and disadvantages of each option prior to commencing a CTC study.


Related Posts